Welcome to our dedicated page for Crinetics Pharmaceuticals SEC filings (Ticker: CRNX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, providing structured access to its current reports, financial updates, and material event announcements. These documents offer detailed insight into how Crinetics manages its endocrine-focused pharmaceutical business, including product approvals, clinical milestones, financing activities, and governance matters.
Crinetics uses Form 8-K to report significant events. Recent 8-K filings have addressed topics such as U.S. FDA approval of PALSONIFY™ (paltusotine) for adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option, research and development updates tied to major medical meetings, and financial results for specific reporting periods. Other 8-Ks describe executive transitions, including changes in senior medical leadership and related transition and advisory agreements, with details on severance, advisory compensation, and equity award treatment.
Crinetics also files 8-Ks in connection with its capital markets activity, such as underwritten public offerings of common stock under an automatically effective shelf registration statement. These filings typically outline the size of the offering, use of proceeds—such as funding commercialization of PALSONIFY, research and development of product candidates, and general corporate purposes—and the involvement of underwriters.
In addition to 8-Ks, investors can expect to find annual reports on Form 10-K and quarterly reports on Form 10-Q in the broader SEC record, which provide more comprehensive discussions of Crinetics’ endocrine and endocrine-related tumor programs, risk factors, and financial statements. Form 4 filings, when present, disclose insider transactions in CRNX equity, offering visibility into trading by directors and officers.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping users quickly identify information about product approvals, clinical trial progress for candidates such as atumelnant and CRN09682, equity offerings, and leadership changes. Real-time updates from EDGAR, combined with simplified explanations of complex sections in 10-K and 10-Q reports, make this page a practical resource for reviewing Crinetics’ regulatory history and ongoing disclosure obligations.
Crinetics Pharmaceuticals, Inc. is an endocrine‑focused pharmaceutical company that has transitioned to commercial stage with PALSONIFY (paltusotine), its first FDA‑approved product. PALSONIFY was approved on September 25, 2025 as the first once‑daily oral somatostatin receptor ligand for adults with acromegaly who had an inadequate response to surgery or cannot undergo surgery.
The company is pursuing broader use of paltusotine, including a Phase 3 CAREFNDR trial in carcinoid syndrome and a European marketing application, where CHMP issued a positive opinion in February 2026. Crinetics is also advancing atumelnant, an oral ACTH antagonist in Phase 3 CALM‑CAH and pediatric BALANCE‑CAH studies for congenital adrenal hyperplasia, and preparing a seamless Phase 2/3 trial in ACTH‑dependent Cushing’s syndrome.
CRN09682, the first candidate from its nonpeptide drug conjugate platform for SST2‑positive tumors, entered a Phase 1/2 BRAVESST2 study after IND clearance in 2025. Crinetics holds a broad patent estate extending into the 2040s, partners selectively in Japan and certain technologies, and emphasizes rare endocrine diseases with significant unmet need.
Crinetics Pharmaceuticals reported fourth quarter and full year 2025 results marked by the U.S. launch of PALSONIFY for acromegaly and its first product revenue. Fourth quarter revenue was $6.2 million, including $5.4 million in net product revenue from PALSONIFY, with more than 200 enrollment forms and over 125 prescribing healthcare providers in the quarter.
For 2025, total revenue was $7.7 million, while research and development expenses reached $332.1 million and selling, general and administrative expenses were $191.3 million, leading to a net loss of $465.3 million. The company used $326.2 million of cash, below prior guidance, and ended 2025 with $1.0 billion in cash, cash equivalents and investment securities, rising to about $1.4 billion after a January 2026 equity offering that raised approximately $380 million in net proceeds.
Crinetics highlighted significant pipeline progress, including FDA approval of PALSONIFY in September 2025, a positive CHMP opinion in Europe, multiple pivotal trials for paltusotine and atumelnant, and the first clinical candidate from its nonpeptide drug conjugate platform. For 2026, the company guides to GAAP operating expenses of $600–650 million and non-GAAP operating expenses of $480–520 million, reflecting continued investment in commercialization and late-stage development.
Crinetics Pharmaceuticals President & CEO Richard Scott Struthers reported equity awards and updated his holdings. He received a stock option for 228,000 shares of Common Stock at an exercise price of
Crinetics Pharmaceuticals Chief Financial Officer Tobin Schilke reported new equity awards. On
He also received 32,000 shares of common stock as a grant described in the footnotes as restricted stock units. These units vest 25% annually beginning on
The stock options vest and become exercisable in 48 equal monthly installments starting from the vesting commencement date of
Crinetics Pharmaceuticals, Inc. Chief Operating Officer Jeff E. Knight reported receiving new equity awards. He was granted stock options for 55,000 shares of common stock at an exercise price of
The RSUs vest with 25% of the award vesting annually beginning on
After these awards, Knight directly owned 121,929 shares of common stock, which includes 438 shares acquired under the company’s employee stock purchase plan, as well as 55,000 stock options from this grant.
Crinetics Pharmaceuticals, Inc.Stephen F. Betz
He received a stock option covering 47,000 shares of common stock, vesting in forty-eight equal monthly installments starting from a vesting commencement date of February 23, 2026. He also received 30,000 restricted stock units, each representing a right to receive one share of common stock, with 25% vesting annually beginning on March 1, 2027. Both awards were reported at a price per share of $0.00, reflecting grants rather than open‑market purchases.
Crinetics Pharmaceuticals, Inc. reported that Chief Commercial Officer Isabel Kalofonos received new equity awards on February 23, 2026. She was granted stock options for 55,000 shares of common stock at an exercise price of $0.00 and 34,000 shares of common stock as restricted stock units.
The restricted stock units represent the right to receive common shares, with 25% vesting annually beginning on March 1, 2027. The stock option vests in forty-eight equal monthly installments starting from February 23, 2026, aligning the CCO’s compensation with long-term company performance through time-based vesting.
Crinetics Pharmaceuticals, Inc. (CRNX) received an updated ownership disclosure from Farallon-affiliated investment funds and managers. The Schedule 13G/A (Amendment No. 1), triggered by a 12/31/2025 event date, reports aggregate beneficial ownership of 8,024,098 common shares, representing 8.5% of the company.
The largest single holder listed is Farallon Healthcare Partners Master, L.P., with 4,682,318 shares, or 4.9% of the class. Farallon Partners, L.L.C. is reported as beneficial owner of 7,826,338 shares, or 8.2%. All Farallon entities report only shared, and no sole, voting or dispositive power.
The amendment updates the group’s internal governance. Effective 1/1/2026, Avner A. Husen became a member/manager of the Farallon general partner entities and may be deemed a beneficial owner of the Farallon funds’ shares. Effective 12/31/2025, Richard B. Fried, Rajiv A. Patel and William Seybold ceased those roles and may no longer be deemed beneficial owners. The reporting persons file under Rule 13d-1(c) and certify the shares are not held to change or influence control of Crinetics.
CRNX insider Dana Pizzuti has filed a Form 144 to sell 10,000 shares of common stock. The planned sale, through Morgan Stanley Smith Barney LLC on NASDAQ around February 2, 2026, has an aggregate market value of
The 10,000 shares were acquired the same day via a cash exercise of stock options. Over the prior three months, Pizzuti sold a total of 15,000 common shares in three 10b5-1 plan transactions, with gross proceeds of
Crinetics Pharmaceuticals, Inc. reported a leadership title change for one of its senior executives. Effective January 2, 2026, Jeff Knight’s role was updated from Chief Operating Officer to Chief Development and Operating Officer. The board of directors approved this change on January 20, 2026, to better reflect his existing responsibilities and scope of duties.
The company stated that there were no changes to Mr. Knight’s compensation arrangements in connection with this new title. Crinetics also confirmed that there are no arrangements or understandings with any other person related to his selection for this role, no family relationships with any director or executive officer, and no reportable related party transactions involving him. His business experience is described in the company’s 2025 proxy statement, which is incorporated by reference.